• 55% of evaluable patients achieved an objective response
  • Median duration of response not reached, with a median follow-up of 7.1 months

SAN DIEGO--(BUSINESS WIRE)--Dec. 11, 2011-- New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma (DLBCL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Data presented at the meeting focused on a cohort of 13 patients with DLBCL, of which 11 received the target dose and were evaluable for response. Of these 11 patients, 6 (55%) achieved an objective response following treatment with blinatumomab. 4 of 11 patients (38%) achieved a complete response. Patients were treated with a single course of blinatumomab induction therapy for up to eight weeks. As of October 2011, 5 of 6 patients had ongoing responses for up to 16.6 months. The median duration of response had not been reached with a median observation time of 7.1 months.

All patients enrolled in this study had received prior rituximab-containing regimens. Most had received three or more prior lines of therapy, including 8 of 13 patients with prior autologous stem cell transplant.

"The level of activity observed with a single agent in this heavily pre-treated patient population is unusual," said Andreas Viardot, M.D., Department of Medicine III, University of Ulm. "We look forward to further exploring blinatumomab's activity in patients with relapsed diffuse large B cell lymphoma."

The most common clinical adverse events were grade 1 or 2 and included flu-like symptoms, pyrexia, headache, and fatigue. These were most frequently seen at the onset of treatment. The clinically most relevant adverse events were fully reversible central nervous system (CNS) events. A key objective of this study was to optimize the type and timing of steroid administration to mitigate the risk of developing CNS adverse events. Notably, no discontinuations due to CNS events were observed in the five patients who received an optimized steroid schedule including dexamethasone administration starting 12 hours before the start of blinatumomab infusion.

"With an improved steroid pre-medication schedule, we have successfully treated patients with relapsed diffuse large B cell lymphoma at the blinatumomab target dose," said Jan Fagerberg, M.D., Ph.D., Micromet's Senior Vice President and Chief Medical Officer. "We plan to initiate in 2012 a phase 2 trial in patients with diffuse large B cell lymphoma."

Study design

This open-label, single-arm phase 1 study was designed to assess the safety and efficacy of blinatumomab in 76 patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) whose disease progressed despite prior treatment. Endpoints included safety, objective response rate, progression-free survival, time to disease progression, and overall survival.

Blinatumomab Experience in Indolent Lymphoma and Mantle Cell Lymphoma

Results from this study were reported at the 2011 Annual International Conference on Malignant Lymphoma. At the therapeutic dose level of 60 micrograms per meter squared per day, 71% of NHL patients (20 of 28) achieved an objective response, including 10 out of 12 follicular lymphoma patients and 4 out of 5 mantle cell lymphoma patients. The most common adverse events were early, transient, fully reversible and did not require discontinuation of treatment. The clinically most relevant adverse events were fully reversible and manageable CNS events.

Phase 2 Trial in Patients with Relapsed Diffuse Large B-Cell Lymphoma

Based on the results reported at ASH, in 2012 the Company plans to initiate a phase 2 study intended to further evaluate the efficacy and safety of blinatumomab in patients with relapsed/refractory DLBCL. The primary endpoint of the study will be objective response rate according to Cheson criteria. Secondary endpoints will include duration of response, time to progression, overall survival, and incidence and severity of adverse events. Results from this trial will inform the Company's registration strategy in this patient population.

Conference Call and Webcast

Micromet management will host a meeting for the investment community on Monday, December 12 beginning at 12 PM PT to review the data presented at ASH. To participate in the event, please dial 888-567-1602 (domestic) or 201-604-5049 (international) and reference the Micromet ASH analyst event. The presentation will be available via webcast in the Investors and Media section of the Micromet. The archived webcast will be available for 30 days at .

About Blinatumomab

Blinatumomab (MT103) is a next-generation monoclonal antibody-based therapeutic designed to direct the body's cell destroying T-cells against target cells expressing CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.

About Micromet, Inc.

Micromet (NASDAQ: MITI) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab and the potential safety, efficacy and utility of blinatumomab and the planned initiation of future clinical trials. You are urged to consider statements that include the words "will," "believes," "potential," "plans," "intends," "may," "suggests," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab does not demonstrate safety and/or efficacy in on-going or future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2011, filed with the SEC on November 8, 2011 as well as other filings by Micromet with the SEC. Micromet cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Micromet also disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Reference:

1. Viardot A, et al. Blood. 2011;118(21):711-712 [abstract 1637]

Source: Micromet, Inc.

Micromet, Inc.
Jennifer Neiman, 240-235-0246
Director, Corporate Communications
jennifer.neiman@micromet.com

distribué par

Ce noodl a été diffusé par Micromet Inc. et initialement mise en ligne sur le site http://www.micromet-inc.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2011-12-11 14:57:01 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.